Merck & Co (MRK)

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid mixed product performance.

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be around $64.75 billion, close to analysts’ estimates. Its non-GAAP profit of $2.58 per share was 9.9% above analysts’ consensus estimates.

Merck Q3 2025 earnings beat estimates with strong sales and EPS growth, driven by KEYTRUDA and WINREVAIR, yet shares fell on guidance.

The company sells a notable vaccine to prevent human papillomavirus. But sales are struggling.

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a

Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.

These bargains could prove good for your financial health.

Flash Purchasing Managers' Index (PMI) data, a critical economic bellwether, continues to command significant attention from financial markets and policymakers alike. Released typically a week or two ahead of final PMI figures and other major government economic reports, this forward-looking indicator provides an invaluable, real-time snapshot of the health and

ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop

Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally

The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift towards personalized medicine. Artificial intelligence (AI) stands at the forefront of this revolution, offering unprecedented capabilities to overcome long-standing challenges and accelerate the delivery of tailored, effective treatments. [...]

That's plenty of time for these drugmakers to move past their challenges.

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached an unprecedented all-time high. This bullish sentiment in equities, however, unfolded against the backdrop of a

The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer.

The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements in generative AI are now yielding tangible benefits, delivering measurable returns across clinical and administrative domains. This shift is further amplified by the emerging paradigm of 'agentic AI,' which promises [...]